Month-by-Month Launch Timeline for a Biopsy Device Company

Lenders and investors read a medical device plan from the back forward. They look first at the date of the first sale, then work out how much cash the company burns before it arrives. A biopsy device is a Class II instrument in the United States, which means the calendar is driven by testing and paperwork rather than by building a shopfront. The sequence below assumes a single-use core needle or small-gauge vacuum-assisted probe with a known predicate, a founder who is a clinician or biomedical engineer, and a contract manufacturer rather than an in-house production line.

Months 0 to 3: Clinical need, predicate search and design inputs

The first quarter is cheap and decides everything after it. Write a one-page statement of the clinical problem in the words a radiologist, interventional pulmonologist or urologist would use: tissue yield per pass, sample fragmentation, seeding risk along the needle track, procedure time, or the cost of a second biopsy when the first returns non-diagnostic. Search the FDA 510(k) database for cleared biopsy needles, starting from the product code for gastroenterology-urology biopsy instruments, and shortlist two or three predicates. If you cannot find a predicate whose intended use matches yours, stop and price the De Novo route before spending anything else. Hold two or three paid design-input interviews with practising proceduralists and record what they say verbatim, because those quotes go straight into your market and risk sections.

• Draft the intended-use statement and indications. A single added anatomical site can change the product code and the testing you owe.
• Open a design history file from day one, even if it is a shared folder with dated documents. Retrofitting design controls costs far more than starting them.
• File a provisional patent application before showing a prototype to any clinician outside a signed NDA.

Months 3 to 9: Prototypes, bench testing and quality system

Move from sketches to machined or 3D-printed prototypes, then to a first pilot build from the contract manufacturer. Bench work for a needle covers cutting force, sample length and weight on tissue-mimicking material, bend and fracture strength, hub bond strength, and compatibility with the guidance equipment it will be used alongside, whether that is a coaxial introducer, an ultrasound guide or a stereotactic table. Stand up an ISO 13485 aligned quality system in parallel. The FDA Quality Management System Regulation, which took effect on 2 February 2026, incorporates ISO 13485 by reference, so a quality manual written to ISO 13485 serves both US and international filings.

• Select an electronic quality management system early. Greenlight Guru and Qualio both sell packages aimed at early-stage device companies, and either is cheaper than hiring a quality manager in year one.
• Book sterilisation and packaging validation slots with a contract lab now. Lead times for ethylene oxide validation runs are measured in weeks, and a missed slot pushes the whole programme.
• Decide the commercial intent of the device and write it into the risk file under ISO 14971.

Months 9 to 15: Biocompatibility, shelf life and submission

Biocompatibility testing under ISO 10993 for a device with limited tissue contact is typically a six-to-twelve-week job once the final materials are frozen. Accelerated ageing studies establish an initial shelf life claim, commonly one to three years, with real-time ageing continuing in the background. Package validation to ISO 11607 follows, including transit simulation. Compile the 510(k) once testing reports are signed, and pay the user fee at submission. The FDA aims to reach a decision on a 510(k) within 90 FDA days, excluding the time a file spends on hold awaiting your answers, and industry commentary puts the typical elapsed time from submission to decision at roughly 120 to 175 calendar days once holds are counted (Qualio, FDA approval timeline guide). Budget the longer figure in the cash plan.

Months 15 to 24: Clearance, first lot and first accounts

Clearance does not produce revenue. It permits you to ship to a customer, and hospitals buy through value analysis committees that meet monthly or quarterly. Plan for a six-to-nine-month sales cycle from first clinical champion to first purchase order, running in parallel with your last submission months so the two clocks overlap. Order the first commercial lot only after you hold a signed evaluation agreement or a distributor commitment, because sterile single-use inventory carries an expiry date and a dead lot is a write-off.

Put these four numbers on a single page of your plan. They are the figures a loan officer or angel will test first, and they are the ones most first-time device founders understate.

What It Costs to Reach First Sale: $436K to $1.6M

The figure most pages quote for a medical device startup is a generic "$100,000 to $500,000", which means nothing for a biopsy device. The spread comes from three decisions: whether you build a simple needle or a motorised vacuum-assisted system with a reusable driver, whether your 510(k) needs clinical data or only bench data, and how much stock you pre-build. The table below is an Avvale planning model for a single-use needle product, expressed in US dollars with a sterling equivalent at roughly 0.79. It is an estimate for planning, not a quote; replace each line with supplier quotations before you submit a plan to a lender.

Line items to put in your sources and uses table

• Product design and engineering: $90K-$300K (£71K-£237K). Industrial design, needle geometry, handle or firing mechanism, CAD, and design reviews. A founder with machining or injection-moulding experience lands at the low end.
• Tooling and pilot builds: $60K-$250K (£47K-£198K). Moulds for hubs and handles are the large item. Needle cannula grinding and tip geometry are usually bought from a specialist rather than tooled.
• Verification and validation testing: $90K-$370K (£71K-£292K). This combines bench performance ($20K-$60K), ISO 10993 biocompatibility ($30K-$90K), sterilisation validation and shelf-life ageing ($25K-$100K), and tissue-yield or cadaver work ($20K-$150K) where your predicate comparison requires it.
• Regulatory consultant, FDA fees and registration: $33K-$117K (£26K-£92K). The 510(k) fee for FY2026 is $26,067, or $6,517 for a CDRH-certified small business, and the annual establishment registration fee is $11,423 (ProVision FDA, FY2026 user fees). Consulting fees quoted for a 510(k) typically run from $15,000 to $80,000 depending on testing guidance and complexity.
• Quality system and software: $25K-$80K (£20K-£63K) for ISO 13485 documentation, supplier audits and an electronic QMS licence.
• Intellectual property: $25K-$70K (£20K-£55K) for a provisional followed by a utility filing and a freedom-to-operate search. The needle space is crowded with expired and live patents; skipping the search is the commonest false economy.
• Product liability and clinical trial insurance: $8K-$30K (£6K-£24K) a year. Hospitals will ask for a certificate before an evaluation.
• Legal, entity set-up and contracts: $15K-$40K (£12K-£32K), including supply agreements and distributor terms.
• First commercial lot and safety stock: $50K-$200K (£40K-£158K). Sterile single-use stock is a cash cost you carry for months before it is invoiced.
• Clinical education, advisory board and conference presence: $40K-$150K (£32K-£119K). A booth at a radiology or breast imaging meeting is a five-figure line on its own.

How funding actually works for a device company

A common mistake is to plan a pre-revenue device company around a conventional bank loan. The SBA 7(a) programme, which allows loans up to $5 million, is built for businesses with cash flow or hard collateral, and a company with no cleared product and a laptop-based design office has neither. Medical device manufacturers file under NAICS 339112 (surgical and medical instrument manufacturing), and SBA 7(a) becomes realistic after clearance, when you have purchase orders, inventory and equipment to finance. Before that, the money comes from other places.

• Founder, friends and angels: usually $150K-$500K against a prototype and a design-input document. Angels who have worked in device companies will read your regulatory section before your market section.
• NIH and NCI SBIR/STTR grants: non-dilutive funding for cancer diagnostics and instrumentation. Phase I awards are in the low hundreds of thousands of dollars; confirm the current figure in the active solicitation. Applications reward a named clinical collaborator and a testable aim.
• University licensing: the University of Arizona licensed a next-generation needle biopsy design based on electrosurgery to a startup called Data Driven Diagnostics Sciences, which shows how an academic invention becomes a company (University of Arizona Tech Launch Arizona).
• Strategic and VC capital: Raleigh-based UVision360 had raised about $8.1 million in total when it secured FDA clearance for its LUMINELLE 360 degree biopsy sheath in July 2021 (WRAL TechWire). That is a realistic order of magnitude for an all-in-one instrument platform.
• UK routes: Start Up Loans of up to £25,000 will not fund a device programme, but SEIS and EIS investors will, since SEIS allows a company to raise up to £250,000 at the earliest stage with 50% income tax relief for the investor. Innovate UK grant competitions in medtech and the NIHR i4i programme are the grant equivalents of SBIR.

Whatever the mix, the plan should state the runway the money buys in months, tied to the milestones in the timeline above, and the dilution or repayment obligation at each stage. Investors in devices fund milestones, not calendar quarters.

Suppliers and Manufacturing Partners You Will Talk To

Almost no biopsy device startup makes its own needles. Cannula grinding, cutting-edge geometry and cleanroom assembly are specialist skills, and a contract partner with an existing ISO 13485 certificate saves you the audit burden. The names below are established suppliers in minimally invasive instruments and needle-based devices. Treat the list as a starting set of introductions rather than an endorsement; capacity, minimum order quantities and pricing change, so request quotations from at least three before choosing.

Two practical points save founders money. First, own your drawings and tooling in writing; a contract manufacturer who holds your moulds holds your roadmap. Second, qualify a second source for the needle cannula before commercial launch. Single-source sterile consumables are the standard way a promising hospital contract fails: the first stockout triggers a competitor trial the next week.

Geography matters in this industry more than most. The Twin Cities corridor in Minnesota, Greater Boston, Southern California around Irvine and the Research Triangle in North Carolina each contain dense clusters of device engineers, contract manufacturers and regulatory consultants. In the UK, the Cardiff and Newport area, the Oxford-Cambridge arc and Greater Manchester host medtech clusters with university spinout pipelines. Locating within a day's drive of your cannula supplier cuts a week from every iteration cycle.

FDA, UK and EU Clearance Routes for a Biopsy Device

Regulatory strategy is the longest section of a credible biopsy device plan and the one most generic templates skip. A biopsy needle that cuts or aspirates tissue for examination falls under the gastroenterology-urology biopsy instrument regulation, 21 CFR 876.1075, and is a Class II device with product code KNW, as listed in the FDA product classification pages indexed by Innolitics. Other anatomical sites and energy sources have their own codes, so confirm yours in the FDA classification database before committing to a predicate.

United States

• Traditional or Abbreviated 510(k): the usual route for a needle with a cleared predicate. FY2026 fee of $26,067 standard or $6,517 for a certified small business. Plan for an Additional Information request; most files get one.
• De Novo classification: required when no suitable predicate exists, for example a biopsy device that adds a genuinely new energy or sensing mode. The FY2026 fee is $173,782, or $43,446 for small businesses (FDAHELP, FY2026 fee table), and review runs longer than a 510(k).
• Establishment registration and device listing: annual fee of $11,423 for FY2026, with no small business reduction, though a hardship waiver is available for the smallest companies.
• Quality Management System Regulation: in force from 2 February 2026, aligned with ISO 13485. Design controls, supplier controls, complaint handling and CAPA all need to exist in practice before an inspection.
• Labelling and UDI: a unique device identifier on each package and an entry in the FDA GUDID database.
• Medical device reporting: a procedure for reporting deaths, serious injuries and malfunctions, which for needles most often means fractured tips left in tissue.
• Product liability cover: hospitals and group purchasing organisations will require a certificate, commonly at $1M per occurrence and $3M aggregate.

United Kingdom

Great Britain regulates devices under the UK Medical Devices Regulations 2002, administered by the MHRA. Devices are classified I, IIa, IIb or III, and an invasive short-term device such as a biopsy needle commonly falls into Class IIa, which requires conformity assessment by a UK Approved Body and registration with the MHRA before placing it on the market (GOV.UK, regulating medical devices in the UK). A manufacturer based outside the UK must appoint a UK Responsible Person.

• UKCA marking or recognised CE marking: CE-marked devices continue to be accepted in Great Britain until June 2028 for most devices, or June 2030 for those compliant with the EU MDR or IVDR, and the MHRA launched a consultation in March 2026 on whether to recognise CE marks indefinitely (Mills & Reeve). Build both outcomes into your plan.
• International reliance: the MHRA has set out a route that lets manufacturers use US, Canadian or Australian approvals to speed access to Great Britain. A cleared 510(k) therefore strengthens the UK case.
• MHRA registration: all manufacturers placing devices on the Great Britain market must register the manufacturer and the device.
• NHS procurement: trusts buy through frameworks run by NHS Supply Chain and regional collaborative procurement hubs. A UK distributor with existing framework listings is usually quicker than a direct bid.
• Clinical waste and sharps rules: relevant to your instructions for use and to any hospital evaluation protocol.

European Union and other markets

• EU MDR (Regulation 2017/745): a needle for tissue sampling is typically Class IIa and needs a notified body. Published ranges for Class IIa total certification effort run from 9 to 18 months, with notified-body fees in the low tens of thousands of dollars, and the all-in cost of CE marking often lands between EUR 32,000 and EUR 110,000 (MedEnvoy). Notified bodies include BSI Netherlands, TUV SUD and DEKRA; booking an application slot can take months by itself.
• Canada: Health Canada medical device licence for Class II products, supported by an MDSAP certificate or equivalent quality system evidence.
• United Arab Emirates: registration with the Ministry of Health and Prevention through a local authorised representative, usually relying on an existing FDA clearance or CE mark.

The sequencing decision belongs in your plan. Most US-first biopsy companies file a 510(k), launch domestically, and use that clearance as the reliance basis for Great Britain, Canada and several Gulf markets, deferring the EU MDR certificate until a distributor commits to volume. That ordering keeps early cash for the market where your pricing is highest.

Revenue Model and Unit Economics

A biopsy device company earns money on the instrument itself or on a razor-and-blade system. The first is a simple disposable: a needle, a probe or a sheath sold per procedure. The second is a reusable driver or console sold or placed once, with a disposable probe sold on every case. Hospitals price the two very differently, and the plan has to choose one and defend it.

Four revenue models side by side

The gross-margin and royalty ranges above are Avvale planning assumptions drawn from our work with medical device plans, not published industry benchmarks; test them against your own bill of materials and distributor quotations.

A worked unit-economics example

Take a 14-gauge disposable core needle with a spring-loaded handle. Assume a US list price of $95 per unit to a hospital through a distributor who keeps 25%, so the company invoices the distributor $71.25. Cost of goods at a pilot volume of 5,000 units a year is $24.50, made up of $9.20 for the cannula, $6.10 for moulded components, $3.40 for assembly and inspection, $3.30 for sterilisation and $2.50 for packaging. That leaves a gross profit of $46.75 per unit, or 65.6% of invoiced revenue. At 20,000 units a year the unit cost falls to about $17.80 through mould amortisation and better cannula pricing, lifting gross margin to roughly 75%.

Now scale it. A busy breast imaging centre may perform 600 to 1,200 image-guided biopsies a year; a three-hospital health system can pass 3,000. Win eight accounts averaging 900 needles a year and you are at 7,200 units, or about $513,000 in net revenue. Add the year-two expansion to 25 accounts and you reach 22,500 units and $1.6 million. Fixed costs for a lean team of seven (a chief executive, a quality and regulatory lead, an engineer, two clinical sales specialists, a customer-support coordinator and a part-time finance lead) land near $1.3 million a year including field travel and conferences, which places break-even at about 28,000 units. That is why the sample plan below shows break-even in the third year rather than the second.

The numbers hospital buyers use against you

Value analysis committees compare cost per procedure, not cost per needle. If your device raises diagnostic yield, even by two or three percentage points, the repeat biopsy it avoids is worth far more than the unit price gap. In the United States a repeat image-guided biopsy bills in the hundreds of dollars for the procedure alone before imaging, pathology and clinic time are counted. A defensible plan expresses your premium as an avoided-cost calculation with a source for the baseline non-diagnostic rate, and it is more persuasive than any brand claim.

Reimbursement works indirectly. Needle biopsies are paid under the procedure codes the hospital or imaging centre bills, so the device is a cost inside a procedure payment rather than a separately reimbursed item. You are selling to the cost side of someone else's budget, which is why price ceilings in group purchasing contracts matter so much to your model.

The Biopsy Device Market in 2026: Size, Share and Who You Compete With

Published estimates for the global biopsy device market in 2025 cluster between about $2.4 billion and $2.7 billion, with compound growth forecasts between roughly 4.3% and 7.2% a year depending on the research house. Market Research Future, Precedence Research, SNS Insider and others sit inside that range, and the gap is mostly methodology: whether they count only needles and probes, or also guidance systems, markers and consumables (Global Market Insights projects growth of around 6% a year from 2025 to 2034). For a business plan, use the lower consistent range and show the source for each number you quote.

Regionally, North America accounts for roughly 40% of revenue, Europe holds about 26% to 27%, and Asia Pacific, at about 23%, is the fastest growing, led by China and India. In the United States alone, more than a million breast biopsies are performed each year and about 80% of them find benign disease, which tells you where screening volume sits and why a lower-cost, higher-yield needle has a real audience. Prostate, lung, thyroid and liver biopsy each have their own guidance method and their own competitive set, so a plan that says "all biopsy" is a plan that has not chosen a beachhead.

The competitors you must name in your plan

Breast biopsy, the largest segment, is a concentrated market. Industry research puts Hologic at about 60% to 65% of the vacuum-assisted breast biopsy market on the strength of its Brevera, Affirm and Eviva systems, with Devicor Medical Products (the Mammotome line, owned by Danaher) and BD (EnCor and Magnum systems) as the other two major players. Argon Medical Devices competes in core needle products with BioPince and SuperCore, and Olympus is a challenger in endoscopic biopsy (MarketsandMarkets). Entering against a 60% incumbent is not a pricing exercise.

A smaller company is more likely to succeed with a narrow clinical wedge than a broad attack. UVision360 built an all-in-one office gynaecology platform in which a biopsy sheath is a single feature; its pitch rested on "no extra instruments" rather than on beating a giant at its own game. Your plan should name your wedge, such as image-guided lung biopsy with a lower pneumothorax rate, and then show the three or four accounts in a single region where you have a clinical champion ready to run the first fifty cases.

Questions Founders Search For Before They Write the Plan

What class of device is a biopsy needle?

In the United States, a biopsy needle that removes tissue by cutting or aspiration is a Class II device regulated under 21 CFR 876.1075 with product code KNW. In Great Britain and the EU, a short-term invasive needle is commonly Class IIa. Your classification depends on your intended use, so write that statement carefully and have a regulatory consultant confirm it.

How much does a 510(k) cost in total?

The FDA fee is only the visible part. Published guidance puts the whole programme for a 510(k), including testing, consulting, quality system set-up and the fee, at $20,000 to $80,000 or more for simple devices, and a complex or novel device can run from $30,000 to over $500,000 (MedDeviceGuide). The model in this guide puts the filing items inside a larger launch budget because design, tooling and inventory dominate the total.

How long does a 510(k) take?

The FDA's own goal for a decision is 90 FDA days, excluding hold time. Third-party commentary reports averages of 120 to 175 calendar days under current conditions, with 70% to 80% of files exceeding the 90-day target once holds are included. Show a base case of five months in your timeline.

Can I sell a biopsy device in the UK with only an FDA clearance?

Not automatically. You need UKCA or an accepted CE mark, a Class IIa approved-body assessment, and MHRA registration. The planned international reliance route is intended to shorten the process for devices already cleared in the US, but it is not yet a substitute for registration, so treat it as an upside in the plan rather than the base case.

Do I need clinical trials for a biopsy needle?

For a 510(k) with a close predicate, bench, biocompatibility and sometimes cadaveric or animal tissue data are normally enough. Clinical data is expected for De Novo requests and for new technology such as an energy-based or sensing biopsy needle. A usability study with clinicians is cheap insurance in either case.

Sample Plan Preview: Meridian Needle Systems

The preview shows how the executive summary and forecast pages of a finished biopsy device plan look. Meridian is a fictional composite, set in Raleigh, North Carolina, and its numbers follow the unit-economics example above.

What the Biopsy Device Template Contains

The template follows the order investors and lenders read a medical device plan. Each heading carries prompts written for a device company rather than a shop or a service business, so you are answering questions a clinician-investor would actually ask.

• Executive Summary: clinical problem, device, regulatory pathway, funding ask and the milestone the money buys.
• Clinical Need and Product Description: intended use, anatomy, procedure workflow and how your device changes it.
• Regulatory Strategy: product code, predicate table, 510(k) versus De Novo reasoning, UKCA, CE and reliance plan, with dates.
• Market and Competitor Analysis: segment sizing, incumbent share, and the wedge you are choosing.
• Quality System and Manufacturing Plan: contract manufacturer, second source, sterilisation and release testing.
• Go-to-Market: champions, value analysis committee approach, distributor terms and GPO strategy.
• Intellectual Property: patent filings, freedom-to-operate summary and licence terms.
• Team and Advisors: clinical founders, regulatory lead and advisory board biographies.

The optional Financial Forecast add-on, included in the $300/£250 and $1,000/£800 packages, provides a five-year Excel model with an income statement, cash flow, balance sheet, break-even analysis and a milestone-based funding schedule. For related device topics, see our guides for aspiration biopsy needles, breast biopsy devices and angiographic catheters. If you want a broader starting point, our free business plan templates cover the general structure, and our business plan writing service handles regulated products.

Biopsy Device Business Plan FAQ